189_ MMJ Holdings Moves Ahead with FDA Approved Botanical Drug Pathway
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
189_ MMJ Holdings Moves Ahead with FDA Approved Botanical Drug Pathway
-
ナレーター：
-
著者：
Today, we're joined by Duane Boise, CEO of MMJ Holdings, a biopharmaceutical company advancing cannabis-derived medicines through the FDA's botanical Drug Development Pathway. MMJ has received Orphan drug designation for Huntington's disease and multiple sclerosis, and its cannabis-derived soft-gel formulations are now preparing to enter phase 2 clinical trials, helping pave the way for a new era of FDA-validated cannabis medicine.
Duane shares the long road to reaching this milestone, the challenges of bringing cannabis-based therapeutics through the FDA process, and what the future may hold for cannabis as a mainstream medicine.
https://mmjih.com
https://www.linkedin.com/in/duane-boise-b174b9168/
The Innovating Cannabis podcast is produced and hosted by Pam Chmiel, a freelance writer and editor for the Cannabis Industry Journal.
Get in touch with pam@InnovatingCannabisPodcast.com.
LinkedIn Twitter Instagram
Please like the show to help us reach more listeners🙏🏻
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.